{
  "query": "LLY",
  "resolved": {
    "ticker": "LLY",
    "cik": "0000059478",
    "title": "ELI LILLY & Co"
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE1 primary completion in ~41 days",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE1)",
        "detail": "A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes",
        "nctId": "NCT06945419",
        "date": "2026-08"
      },
      "observed": {
        "event": "primary completion in ~41 days",
        "nctId": "NCT06945419"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 2 readout / advance",
        "leadTime": "12-24 mo",
        "baseRate": 0.52,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 52% (Wong/Siah/Lo 2019)",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06945419",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities",
        "nctId": "NCT06672939",
        "date": "2027-12"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT06672939"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06672939",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)",
        "nctId": "NCT06439277",
        "date": "2027-10"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT06439277"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06439277",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)",
        "nctId": "NCT06672549",
        "date": "2027-02"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT06672549"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06672549",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE3 protocol updated 4 days ago",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)",
        "nctId": "NCT06383390",
        "date": "2029-02"
      },
      "observed": {
        "event": "protocol updated 4 days ago",
        "nctId": "NCT06383390"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06383390",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)",
        "nctId": "NCT05738486",
        "date": "2024-05-16"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT05738486"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT05738486",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE2 protocol updated 4 days ago",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)",
        "nctId": "NCT07589595",
        "date": "2028-08"
      },
      "observed": {
        "event": "protocol updated 4 days ago",
        "nctId": "NCT07589595"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07589595",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE1 protocol updated 5 days ago",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE1)",
        "detail": "A Study of LY3439539 in Participants With Alzheimer's Disease",
        "nctId": "NCT07598370",
        "date": "2027-05"
      },
      "observed": {
        "event": "protocol updated 5 days ago",
        "nctId": "NCT07598370"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 2 readout / advance",
        "leadTime": "12-24 mo",
        "baseRate": 0.52,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 52% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07598370",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ELI LILLY & Co (LLY) — PHASE3 protocol updated 3 days ago",
      "entity": "Eli Lilly and Company",
      "ticker": "LLY",
      "cik": "0000059478",
      "tickerConfidence": 0.8166666666666667,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)",
        "nctId": "NCT06739122",
        "date": "2027-12"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT06739122"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06739122",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "ELI LILLY & Co",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": [
      {
        "form": "8-K",
        "date": "2026-05-20",
        "accession": "0001193125-26-232707",
        "items": "8.01,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-05-07",
        "accession": "0000059478-26-000048",
        "items": "5.07"
      },
      {
        "form": "8-K",
        "date": "2026-04-30",
        "accession": "0000059478-26-000043",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-02-04",
        "accession": "0000059478-26-000008",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2025-11-21",
        "accession": "0000059478-25-000271",
        "items": "5.02"
      }
    ]
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-06-21T09:50:25.029Z"
}